Mariangela Goglia
Basal metabolism, myokine levels and disease severity in Amyotrophic Lateral Sclerosis
Autori
- MARIANGELA GOGLIA (NEUROMUSCULAR DISEASES UNIT, DEPARTMENT OF SYSTEMS MEDICINE, TOR VERGATA UNIVERSITY OF ROME, 00133 ROME, ITALY – NEUROLOGIA)
- LAURA BOFFA (NEUROMUSCULAR DISEASES UNIT, DEPARTMENT OF SYSTEMS MEDICINE, TOR VERGATA UNIVERSITY OF ROME, 00133 ROME, ITALY – NEUROLOGIA)
- ERICA FREZZA (NEUROMUSCULAR DISEASES UNIT, DEPARTMENT OF SYSTEMS MEDICINE, TOR VERGATA UNIVERSITY OF ROME, 00133 ROME, ITALY – NEUROLOGIA)
- GIULIA GRECO (NEUROMUSCULAR DISEASES UNIT, DEPARTMENT OF SYSTEMS MEDICINE, TOR VERGATA UNIVERSITY OF ROME, 00133 ROME, ITALY – NEUROLOGIA)
- FRANCESCO GRUOSSO (NEUROMUSCULAR DISEASES UNIT, DEPARTMENT OF SYSTEMS MEDICINE, TOR VERGATA UNIVERSITY OF ROME, 00133 ROME, ITALY – NEUROLOGIA)
- ILARIA PETITTA (NEUROMUSCULAR DISEASES UNIT, DEPARTMENT OF SYSTEMS MEDICINE, TOR VERGATA UNIVERSITY OF ROME, 00133 ROME, ITALY – NEUROLOGIA)
- GIULIA NARDINO (NEUROMUSCULAR DISEASES UNIT, DEPARTMENT OF SYSTEMS MEDICINE, TOR VERGATA UNIVERSITY OF ROME, 00133 ROME, ITALY – NEUROLOGIA)
- GIOVANNI VIETRI (NEUROMUSCULAR DISEASES UNIT, DEPARTMENT OF SYSTEMS MEDICINE, TOR VERGATA UNIVERSITY OF ROME, 00133 ROME, ITALY – NEUROLOGIA)
- MARZIA NUCCETELLI (DEPARTMENT OF EXPERIMENTAL MEDICINE, UNIVERSITY OF TOR VERGATA, ROME, ITALY – BIOCHIMICA CLINICA)
- ANTONINO DE LORENZO (SECTION OF CLINICAL NUTRITION AND NUTRIGENOMIC, DEPARTMENT OF BIOMEDICINE AND PREVENTION, UNIVERSITY OF TOR VERGATA, VIA MONTPELLIER 1, 00133, ROME, ITALY – NUTRIZIONE CLINICA)
- ROBERTO MASSA (NEUROMUSCULAR DISEASES UNIT, DEPARTMENT OF SYSTEMS MEDICINE, TOR VERGATA UNIVERSITY OF ROME, 00133 ROME, ITALY – NEUROLOGIA)
Presentatore
MARIANGELA GOGLIA (NEUROMUSCULAR DISEASES UNIT, DEPARTMENT OF SYSTEMS MEDICINE, TOR VERGATA UNIVERSITY OF ROME, 00133 ROME, ITALY)
Modalità
Poster Session
Abstract
“Amyotrophic lateral sclerosis (ALS) can be considered as a multisystemic disease affecting metabolism and body composition. Abnormal resting energy expenditure (REE) has been reported in ALS patients and its variations have been linked to circulating levels of myokines.
The aim of this study is to investigate metabolic impairment and plasma myokine levels and their possible connection with disease severity.
ALS patients underwent to clinical assessment (ALS-FRS-R, MRC) and blood detection of myokines (irisin, IL-6). Indirect calorimetry and dual X-ray absorptiometry (DEXA) were performed on the same day to assess REE and body composition, respectively.
We enrolled 11 ALS patients and 10 healthy controls. At indirect calorimetry 9 patients were hypometabolic. REE, normalized with fat free mass, directly correlated with irisin levels (p < 0.05). We found no correlations between either REE or irisin and functional scales of disease severity. IL-6 directly correlated with disease duration (p < 0.05) and inversely correlated with MRC sum score (p < 0.05).
Basal metabolism alterations are present in ALS and irisin can be linked to them, independently on disease severity. Conversely, IL-6 could be an indicator of disease progression and severity.
Further investigations are required to clarify whether metabolic abnormalities could have a role in ALS pathogenesis and disease progression or represent a consequence of secondary muscle wasting. Moreover, myokines such as irisin could be useful to investigate alterations of resting metabolic state.”